Mallinckrodt PLC (NYSE:MNK) had its price target cut by Mizuho from $87.00 to $85.00 in a research note released on Friday. They currently have a buy rating on the stock.

Other equities analysts also recently issued research reports about the company. Vetr upgraded Mallinckrodt PLC from a hold rating to a buy rating and set a $88.80 target price for the company in a report on Monday, August 22nd. Jefferies Group restated a buy rating and set a $95.00 target price (up previously from $85.00) on shares of Mallinckrodt PLC in a report on Thursday, August 4th. Piper Jaffray Cos. set a $103.00 target price on Mallinckrodt PLC and gave the company a buy rating in a report on Wednesday, August 3rd. Guggenheim restated a buy rating and set a $98.00 target price on shares of Mallinckrodt PLC in a report on Wednesday, August 3rd. Finally, Leerink Swann set a $91.00 target price on Mallinckrodt PLC and gave the company a buy rating in a report on Wednesday, August 3rd. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $88.65.

Mallinckrodt PLC (NYSE:MNK) opened at 52.70 on Friday. Mallinckrodt PLC has a one year low of $50.90 and a one year high of $85.83. The company has a 50 day moving average of $61.02 and a 200-day moving average of $66.55. The stock has a market capitalization of $5.68 billion, a P/E ratio of 9.94 and a beta of 1.62.

Mallinckrodt PLC (NYSE:MNK) last announced its earnings results on Tuesday, November 29th. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The company earned $887.20 million during the quarter, compared to the consensus estimate of $880.10 million. Mallinckrodt PLC had a return on equity of 17.78% and a net margin of 16.39%. The firm’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.84 earnings per share. Equities research analysts predict that Mallinckrodt PLC will post $7.66 earnings per share for the current fiscal year.

WARNING: “Mallinckrodt PLC (MNK) PT Lowered to $85.00 at Mizuho” was posted by Financial Market News and is the sole property of of Financial Market News. If you are viewing this story on another site, it was copied illegally and reposted in violation of US and international trademark & copyright laws. The legal version of this story can be accessed at http://www.financial-market-news.com/mallinckrodt-plc-mnk-pt-lowered-to-85-00-at-mizuho/1211883/.

Several institutional investors have recently modified their holdings of the stock. Laurel Wealth Advisors Inc. increased its position in shares of Mallinckrodt PLC by 0.5% in the second quarter. Laurel Wealth Advisors Inc. now owns 3,427 shares of the company’s stock valued at $208,000 after buying an additional 16 shares during the last quarter. Norinchukin Bank The increased its position in shares of Mallinckrodt PLC by 0.6% in the third quarter. Norinchukin Bank The now owns 5,767 shares of the company’s stock valued at $402,000 after buying an additional 33 shares during the last quarter. NEXT Financial Group Inc increased its position in shares of Mallinckrodt PLC by 5.2% in the third quarter. NEXT Financial Group Inc now owns 1,676 shares of the company’s stock valued at $117,000 after buying an additional 83 shares during the last quarter. Suntrust Banks Inc. increased its position in shares of Mallinckrodt PLC by 0.3% in the third quarter. Suntrust Banks Inc. now owns 31,844 shares of the company’s stock valued at $2,219,000 after buying an additional 88 shares during the last quarter. Finally, Turner Investments L.P. increased its position in shares of Mallinckrodt PLC by 0.5% in the second quarter. Turner Investments L.P. now owns 19,420 shares of the company’s stock valued at $1,180,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 86.51% of the company’s stock.

Mallinckrodt PLC Company Profile

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.

5 Day Chart for NYSE:MNK

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.